Scientists find natural mimetics of anti-cancer and anti-aging drugs

ea1e96d9-f897-440f-bd93-5244b29f1610articleimage.jpg

04 Dec 2017 --- Researchers from the Biogerontology Research Foundation in the UK, Insilico Medicine, Life Extension and other institutions have announced the publication of a landmark study in the journal Aging on the identification of natural mimetics of metformin and rapamycin.

Metformin, a common Type 2 diabetes drug, and rapamycin, a common anti-rejection drug, have both been shown to have substantial anti-aging and anti-cancer effects in a variety of model organisms. However, both compounds have known side effects and are regulated drugs for existing disease indications, factors that problematize their off-label use as healthspan-extending drugs.

Natural compounds mimic crucial drugs
In the Aging study, the researchers applied deep-learned neural networks to profile the safety and gene- and pathway-level similarity of more than 800 natural compounds to metformin and rapamycin, in an effort to identify natural compounds that can mimic the effects of these anti-cancer and anti-aging drugs while remaining free of the adverse effects associated with them.

“Earlier this year we launched Young.AI, a comprehensive system utilizing the recent advances in deep learning for tracking a variety of aging biomarkers,” says Alex Zhavoronkov, Ph.D., co-author of the study, founder of Insilico Medicine and Chief Science Officer of the Biogerontology Research Foundation. “I hope that the consumers using the Longevity AI will start using it. One of the goals of our group is to identify the combinations of molecules that achieve the desired effects.”

The researchers’ analysis identified many novel candidate metformin and rapamycin mimetics that have been previously unreported as such. In particular, they identified allantoin and ginsenoside as strong mimetics of metformin, epigallocatechin gallate and isoliquiritigenin as strong mimetics of rapamycin, and withaferin A as a strong mimetic of both. Additionally, their analysis also identified four previously unexplored natural compounds as fairly strong mimetics of rapamycin.

“Aging is not recognized as a disease, so we need strong potential geroprotectors of natural origin on the market. Supplements that slow down aging, affecting the key mechanisms of aging at the molecular and cellular level,” says Alexey Moskalev, Ph.D., a co-author of the study.

These findings are significant because, as naturally occurring compounds, such nutraceuticals are not subject to regulation by the FDA and other regulatory bodies. Furthermore, because the researchers induced a deep-learning based classification of the safety profiles associated with these compounds, the novel candidate mimetics the study identified are likely to have less adverse effects than metformin and rapamycin, though this needs to be further validated by clinical testing.

“This study is significant not only for the identification of novel candidate mimetics of metformin and rapamycin – which as natural compounds are not subject to regulatory bodies like the FDA and which have higher-scoring safety profiles as indicated by our deep-learned safety profile classification analysis – but also for demonstrating particularly powerful screening methods that can be applied to the identification of novel and safe mimetics of other known anti-cancer and healthspan-extending drugs and compounds,” says Franco Cortese, co-author of the study and Deputy Director of the Biogerontology Research Foundation.

The paper can be accessed here.

Related Articles

Nutrition & Health News

Energetic growth: Energy boosters add pep to the nutritional space’s step

11 Dec 2017 --- Busy schedules can cause consumers to go through an “energy crisis” – prompting their desire to reach for products that might offer some support to their energy levels. Energy boosters are certainly showing signs of growth in all regions tracked by Innova Market Insights. A CAGR in supplement launches of +208.8 percent in South America from 2012 to 2016 is particularly noteworthy, while Europe is top of the pile worldwide with 28.8 percent of its supplement launches having an energy claim in 2016 and its CAGR amounting to a strong +86.7 percent.

Nutrition & Health News

Soy, cruciferous vegetables linked to fewer breast cancer treatment side effects

11 Dec 2017 --- Consuming soy foods and cruciferous vegetables – such as cabbages, kale, collard greens, bok choy, Brussels sprouts and broccoli – may be associated with a reduction in common side effects of breast cancer treatment in breast cancer survivors, according to a team of scientists led by Georgetown Lombardi Comprehensive Cancer Center. Understanding the role of life style factors with regard to the side effects is important because diet can serve as a modifiable target for possibly reducing symptoms among breast cancer survivors.

Food Ingredients News

NZMP develops innovative fast-digesting milk protein concentrate

08 Dec 2017 --- As part of its ongoing work in the areas of proteins and medical nutrition, Fonterra’s global dairy ingredients B2B brand NZMP has launched a new milk protein concentrate (MPC) coined SureProtein Fast MPC 4868. Compared to standard milk protein offerings, the ingredient is touted as being able to provide muscles with a higher level of amino acids within the first two hours of consumption and is absorbed as quickly as whey protein.

Business News

New Biopolis probiotic mix helps reduce topical steroid use by atopic dermatitis patients

07 Dec 2017 --- Biopolis, majority owned by agricultural processor and food ingredient provider Archer Daniels Midland Company (ADM), has introduced a new probiotic mix designed to reduce the need for topical steroid use by Atopic Dermatitis (AD) patients. The clinical research recently published in JAMA Dermatology, an international peer-reviewed general medical journal, shows the benefits of consuming a mix of probiotics in reducing the need for topical steroids by AD patients.

Business News

Nestle acquires Atrium for US$2.3 billion, extends consumer healthcare portfolio

06 Dec 2017 --- Nestle has agreed to acquire Canadian nutritional health products manufacturer Atrium Innovations from a group of investors led by Permira Funds for US$2.3 billion in cash. Nestle notes that the move for the company, whose 2017 sales are expected to reach almost US$700 million, supports Nestle’s pursuit of growth opportunities in consumer healthcare to complement the company's focus on its high-growth food and beverage categories.

More Articles
URL : http://www.nutritioninsight.com:80/news/scientists-find-natural-mimetics-of-anti-cancer-and-anti-aging-drugs.html